Skip Navigation

JNCI Monographs 2007 2007(37):31-38; doi:10.1093/jncimonographs/lgm007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Moinpour, C. M.
Right arrow Articles by Redman, M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moinpour, C. M.
Right arrow Articles by Redman, M. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

Do General Dimensions of Quality of Life Add Clinical Value to Symptom Data?

Carol M. Moinpour, Gary W. Donaldson, Mary W. Redman

Affiliations of authors: Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA (CMM, MWR); Pain Research Center, University of Utah, Salt Lake City, UT (GWD)

Correspondence to: Carol M. Moinpour, PhD, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center/M3-C102, 1100 Fairview Ave North/Box 19024, Seattle, WA (e-mail: cmoinpou{at}fhcrc.org).

Since global health-related quality of life (GHRQL) reflects broad impacts of treatment, its assessment in an advanced-stage disease trial should add valuable clinical information beyond that of a targeted symptom. Using latent trajectory modeling that allowed for individual trends as well as overall relationships, we reanalyzed three repeated assessments of the present pain intensity from the McGill Pain Questionnaire and the European Organization for Research and Treatment of Cancer Quality of life Questionnaire- Core 30 (QLQ-C30) GHRQL score from a hormone-refractory prostate cancer trial. Within- and between-treatment differences not detected in the original S9916 report of pain palliation and GHRQL suggested substantial individual variation in GHRQL level and change after controlling for within-assessment pain. The treatment had a differential effect on the relationship between GHRQL and pain; we observed an approximately threefold stronger association of reported pain with GHRQL in the docetaxel plus estramustine (D + E) arm compared with the mitoxantrone plus prednisone (M + P) arm (P = .02). In addition, the treatment had an effect, on average, on the rate of change in GHRQL, after controlling for pain level. GHRQL for patients on the M + P arm tended to improve over the assessment period while GHRQL tended to deteriorate for patients on the D + E arm (P = .02). Important, interpretable effects and systematic individual variation in GHRQL remain after controlling statistically for the effects of pain, the targeted symptom, in this trial. In addition, identifying the rate at which a person's GHRQL changes or responds to treatment provides clinically relevant information.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Natl Cancer Inst MonogrHome page
P. A. Ganz and P. J. Goodwin
Health-Related Quality of Life Measurement in Symptom Management Trials
J Natl Cancer Inst Monographs, October 1, 2007; 2007(37): 47 - 52.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.